Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP
New therapeutic strategies are needed for cutaneous T-cell lymphoma (CTCL), and the plant extract ingenol mebutate (PEP005) may be considered. PEP005 has been approved for actinic keratosis, and proapoptotic activities were described in different cancer cells. Here, we aimed to investigate its effic...
Main Authors: | Uly Sumarni, Ulrich Reidel, Jürgen Eberle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/5/987 |
Similar Items
-
Synthesis and Cytotoxicity against K562 Cells of 3-O-Angeloyl-20-O-acetyl Ingenol, a Derivative of Ingenol Mebutate
by: Ming Liu, et al.
Published: (2016-08-01) -
Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study
by: Marine Velin, et al.
Published: (2023-04-01) -
Ingenol mebutate–associated immune thrombocytopenic purpura
by: Hafsa Zuberi, BS, et al.
Published: (2024-04-01) -
Doxycycline PEP can induce doxycycline resistance in Klebsiella pneumoniae in a Galleria mellonella model of PEP
by: Chris Kenyon, et al.
Published: (2023-08-01) -
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects
by: Maria Isabel Ramos Saraiva, et al.
Published: (2018-08-01)